Related Experiment Video
Updated: Mar 26, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction
Wei Ren Chen1, Feng Tian1, Yun Dai Chen1
1Department of Cardiology, PLA General Hospital, at Beijing, China.
Insights
Liraglutide significantly reduced the no-reflow phenomenon in ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI). This cardioprotective effect warrants further investigation in larger clinical trials.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- The no-reflow phenomenon post-percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) is linked to increased mortality.
- Glucagon-like peptide-1 (GLP-1) demonstrates cardioprotective properties against ischemia-reperfusion injury.
Purpose of the Study:
- To investigate the efficacy of liraglutide in mitigating myocardial no-reflow following PCI in STEMI patients.
Main Methods:
- A randomized controlled trial involving 210 STEMI patients undergoing PCI.
- Patients received either liraglutide (1.8 mg) or placebo 30 minutes prior to PCI.
Main Results:
- The prevalence of no-reflow was significantly lower in the liraglutide group (5%) compared to the placebo group (15%; P=0.01).
- Liraglutide administration was a significant determinant for reduced no-reflow.
- Serum high-sensitivity C-reactive protein levels were significantly decreased at 6-hour reperfusion in the liraglutide group.
- No significant difference in major adverse cardiovascular events was observed during 3-month follow-up.
Conclusions:
- Liraglutide shows potential in reducing no-reflow in STEMI patients undergoing PCI.
- Larger-scale trials are recommended to confirm these findings.
Background:
The 'no-reflow' phenomenon after a percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) is a strong predictor of both short- and long-term mortality. Glucagon-like peptide-1 (GLP-1) exerts a cardioprotective effect during ischemia reperfusion injury. We planned to evaluate the effects of liraglutide on myocardial no-reflow after PCI for STEMI.
Methods:
A total of 284 patients with STEMI undergoing PCI were enrolled in this study between September 2013 and March 2015. Of these, 210 patients were randomized 1:1 to receive either liraglutide or placebo 30 min before PCI (1.8 mg).
Results:
The primary end point, the prevalence of no-reflow, was significantly lower in the liraglutide group than in the control group (5% vs. 15%, P=0.01). Administration of liraglutide was consistently identified as a significant determinant for no-reflow ratio. There was a significant decrease in serum high-sensitivity C-reactive protein levels at 6-hour reperfusion in the liraglutide group compared to the control group (0.87 ± 0.09 mg/dL vs. 0.96 ± 0.10mg/dL, P<0.001). During a 3-month follow-up period, no difference was observed in the incidence of major adverse cardiovascular event.
Conclusions:
Liraglutide may be associated with less no-reflow in STEMI, which should be confirmed by larger-scale trials.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
07:59Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:14Myocarditis III: Medical Management